In a rush to bring Xarelto to market, drugmakers Bayer and Janssen Pharmaceuticals skipped needed testing that would have provided the basis for a more accurate warning label, plaintiffs counsel in the latest trial over the blood thinner told a Philadelphia jury Wednesday.

Pensacola, Florida, attorney Neil Overholtz of Aylstock, Witkin, Kreis & Overholtz told jurors during closing arguments in Cooney v. Janssen that, after learning about the efficacy and risks of a 20 milligram dose of the blood thinner, the defendants should have worked to develop a 10 milligram dose—a dose that Overholtz told jurors likely would not have caused the severe bleed that his client, Kevin Cooney, suffered while taking Xarelto.